Actively Recruiting

Phase 3
Age: 18Years - 70Years
All Genders
ID07426120

Efficacy and Safety of a Botanical Total Coumarin Cream in Treating Psoriasis Vulgaris Patients A Double-blind, Randomized, Placebo-controlled Phase III Clinical Trial

Led by Psoriasis Research Institute of Guangzhou · Updated on 2026-02-23

300

Participants Needed

1

Research Sites

26 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating a botanical Total Coumarin topical cream (TC Cream) to see if it helps treat psoriasis vulgaris in adults and to assess its safety. The study compares TC Cream to a placebo cream without active ingredients. The main questions focus on whether TC Cream improves psoriasis symptoms, what medical issues may arise during use, and if it enhances quality of life for those affected. Participants will be randomly assigned to one of two groups: one applying TC Cream and the other applying a placebo cream. Both groups will apply their assigned cream twice daily for 8 weeks. They will visit the clinic every 2 weeks for checkups and tests. The TC Cream is a botanical drug approved in China and studied in previous trials. The placebo cream looks the same but contains no active drug. During the study, participants will have their skin examined and psoriasis severity measured using several scales, including the Investigator's Global Assessment and Psoriasis Area and Severity Index. They will also track symptoms and side effects in a diary. Quality of life will be assessed with questionnaires. Follow-up assessments occur 4 weeks after treatment ends. The involvement lasts for 12 weeks including a 4-week post-treatment observation period.

CONDITIONS

Brief Title

Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age of 18-70 years old, any gender and race
  • Diagnosed with stable phase psoriasis vulgaris
  • Have at least two target lesions suitable for evaluation
  • Women of childbearing age must use approved birth control methods during the 8-week study
  • Psoriasis severity with ISGA score of 2 or higher
  • Body surface area (BSA) involvement between 1% and 20%
  • Signed informed consent
  • No additional exposure to the sun during the study
Not Eligible

You will not qualify if you...

  • Currently pregnant, planning pregnancy, or breastfeeding
  • History of allergic or photosensitive reactions
  • History of serious cardiovascular, cerebrovascular, liver, kidney, blood, or psychiatric diseases
  • History of photosensitive diseases like porphyria or Xeroderma pigmentosa
  • Use of certain psoriasis treatments within 4 weeks before the study (topical treatments, UV therapies, systemic non-biological treatments, investigational therapies)
  • Use of systemic retinoids or biological therapies within 3 months before the study
  • Planned changes to medications that affect psoriasis during the study
  • Allergic reactions to compounds similar to Coumarins

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 8 weeks

Participants apply the assigned cream twice daily to psoriasis-affected areas for 8 weeks and attend clinic visits every 2 weeks for checkups and study tests including skin assessments and symptom evaluations.

Every 2 weeks during treatment (5 visits in total)

Follow-up

Duration - 4 weeks after treatment

Participants attend a final visit 4 weeks after treatment ends to assess the lasting effects of the cream.

1 visit (in-person)

Trial Site Locations

Total: 1 location

1

Department of Dermatology, SUNY Downstate Health Sciences University

New York, New York, United States, 11203

Actively Recruiting

Loading map...

Research Team

J

Jiang Yang, MSc, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Correction of Psoriatic T Cell Signatures by Deucravacitinib

Psoriasis Vulgaris

Actively Recruiting

1 location

Correlation Between Vaspin Gene Polymorphism and Serum Vaspi...

Psoriasis Vulgaris

Actively Recruiting

1 location

Evaluation of Clinical, Perceived and Instrumental Efficacy ...

Acceptability Study

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here